SPEAKER: Now, the evidence to support this actually comes from a clinical trial in which patients with MAC lung disease defined as refractory to standard treatment were then randomized to receive liposomal amikacin inhaled in addition to their current regimen or continue on their current regimen. So it's not a blinded trial, but it is a randomized trial in which there was a greater proportion of patients who achieved culture conversion in the patients treated with the liposomal amikacin product.

It was-- not everybody is going to now respond to therapy. But if you were going from a population in which they were not responding to now over 30% of your patients becoming culture negative, that is a meaningful difference. Keep in mind, those patients, even though the definition was to be on a regimen for at least six months before they were defined as tumor refractory, the average time was in years. And so that was a pretty remarkable finding.